Top Page
Affluent Partners Holdings
(OTC:1466)
Affluent Partners Holdings (1466) vs. iShares MSCI Hong Kong ETF (EWH)
Affluent Partners Holdings Business Overview & Revenue Model
Affluent Partners Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 99.45M | 135.56M | 53.68M | 86.88M | 62.65M | 43.32M |
| Gross Profit | 27.29M | 41.99M | 18.10M | 7.83M | 10.99M | -8.62M |
| EBITDA | -3.60M | 6.26M | -6.32M | 11.13M | -9.73M | -45.45M |
| Net Income | -11.36M | -316.00K | -7.45M | 8.73M | -15.46M | -51.78M |
Balance Sheet | ||||||
| Total Assets | 236.69M | 290.17M | 196.80M | 99.85M | 82.11M | 91.77M |
| Cash, Cash Equivalents and Short-Term Investments | 44.96M | 47.77M | 37.88M | 41.26M | 23.59M | 24.42M |
| Total Debt | 65.71M | 99.93M | 51.19M | 2.76M | 31.84M | 31.56M |
| Total Liabilities | 129.26M | 134.30M | 84.01M | 21.51M | 46.24M | 45.82M |
| Stockholders Equity | 86.63M | 139.28M | 96.31M | 78.34M | 35.87M | 45.95M |
Cash Flow | ||||||
| Free Cash Flow | -15.03M | -32.97M | -6.64M | -21.55M | 1.06M | -16.21M |
| Operating Cash Flow | -14.47M | -30.53M | -6.46M | -21.52M | 1.11M | -16.18M |
| Investing Cash Flow | 4.28M | -846.00K | 4.74M | 35.30M | -60.00K | 138.00K |
| Financing Cash Flow | 18.45M | 41.41M | 819.00K | 3.70M | -1.72M | 6.77M |
Affluent Partners Holdings Technical Analysis
Affluent Partners Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | HK$450.11M | 5.10 | 10.79% | 11.31% | 14.24% | 3.63% | |
70 Outperform | HK$1.65B | 8.22 | 11.44% | 10.41% | -5.19% | -19.96% | |
49 Neutral | HK$563.71M | -14.22 | -2.03% | ― | -41.44% | -209.76% | |
47 Neutral | HK$794.38M | 95.24 | 4.30% | ― | 111.72% | 1.61% | |
46 Neutral | $432.54M | ― | -0.25% | ― | 152.54% | 87.07% | |
43 Neutral | HK$616.04M | -9.57 | -47.04% | ― | -20.65% | -616.18% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
Affluent Partners Holdings Corporate Events
Baijin Life Science Holdings Limited has announced its 2025 Annual General Meeting, which will take place on September 30, 2025, in Hong Kong. The meeting will address ordinary business matters such as the approval of audited financial statements, the re-election of directors, and the re-appointment of the independent auditor. Additionally, a special resolution will be discussed to authorize the directors to issue additional shares and securities, potentially impacting the company’s capital structure and shareholder value.
Affluent Partners Holdings, through its subsidiary Baijin Life Science Holdings Limited, has announced the non-fulfillment of an accumulated profit guarantee related to the acquisition of Tonnett Julis Holdings Limited. The company has decided to pay the compensation amount in cash, which will be allocated towards setting up beauty salons, developing its jewelry business, and as general working capital. This strategic allocation aims to enhance brand awareness and capitalize on growth opportunities in the beauty and jewelry sectors, ensuring the company’s continued market presence and operational stability.
Baijin Life Science Holdings Limited announced its annual results for the financial year ending March 31, 2025, reporting a significant increase in revenue from HK$53,676,000 in 2024 to HK$135,556,000 in 2025. Despite the revenue growth, the company recorded a slight loss of HK$87,000, an improvement from the previous year’s loss of HK$8,545,000, indicating a positive trend in financial performance and potential for future profitability.
Baijin Life Science Holdings Limited, along with its subsidiaries, has announced a significant reduction in its financial losses for the year ending March 31, 2025. The company expects to report a loss of approximately HK$0.1 million, a substantial decrease from the HK$8.5 million loss recorded the previous year. This improvement is attributed to increased revenue and gross profit from its jewelry business segment, a reversal of allowances for expected credit losses, and other net gains, despite some offsetting factors such as impairment loss on goodwill and rising administrative expenses. Trading of the company’s shares remains suspended pending the publication of its annual results.
Baijin Life Science Holdings Limited, a company incorporated in the Cayman Islands, has announced a delay in the publication of its 2025 Annual Results and the dispatch of the 2025 Annual Report. The delay is attributed to changes in the management of its subsidiaries, which were necessary to facilitate the provision of requisite information for audit procedures. The company has appointed Baker Tilly Hong Kong Limited as its new auditors and is working to complete the audit work by late July 2025. The delay in the audit process has also led to a continued suspension of trading. The company aims to publish the audited results by 25 July 2025 and dispatch the annual report by 22 August 2025, subject to the completion of all audit work.
Baijin Life Science Holdings Limited has announced a board meeting scheduled for July 25, 2025, to approve the final results for the year ending March 31, 2025, and consider a final dividend. Trading of the company’s shares remains suspended pending the publication of the annual results, urging caution among shareholders and potential investors.
Baijin Life Science Holdings Limited, a company incorporated in the Cayman Islands, has announced a suspension of trading of its shares on the Hong Kong Stock Exchange. This decision comes as the company has delayed the publication of its 2025 Annual Results. The suspension will take effect from July 2, 2025, until the results are published, indicating potential operational or financial reporting challenges that may impact stakeholders.
Baijin Life Science Holdings Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board is structured with three committees: Audit, Remuneration, and Nomination, each with designated members to oversee various governance functions. This announcement highlights the company’s commitment to maintaining a robust governance framework, which is crucial for its operational integrity and strategic decision-making. The structured board and committee roles are expected to enhance the company’s industry positioning and stakeholder confidence.
Baijin Life Science Holdings Limited has announced a delay in the publication of its annual financial results for the year ending March 31, 2025, due to a longer-than-expected handover process following changes in subsidiary management. The company anticipates publishing the results by July 25, 2025, and assures stakeholders that operations remain normal despite the delay. Trading in the company’s shares may be suspended if the results are not published by June 30, 2025.